Syndax Pharmaceuticals, Inc. announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is currently senior vice president and chief financial officer of Momenta Pharmaceuticals, Inc. where he managed a Series C venture round and various public offerings, including Momenta's initial public offering. Mr. Shea has also served as chief operating officer and chief financial officer at Variagenics, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.69 USD | -4.51% |
|
+4.41% | +9.63% |
07-01 | Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index | CI |
07-01 | Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2500 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.63% | 2.11B | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- SNDX Stock
- News Syndax Pharmaceuticals, Inc.
- Syndax Pharmaceuticals, Inc. Announces Appointment of Richard P. Shea as Independent Director and Chairman of Audit Committee